胰高血糖素样肽-1受体激动剂作为磺脲类药物的附加疗法成功用于治疗新生儿糖尿病
Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of Neonatal Diabetes.
作者信息
Hindsø Morten, Martinussen Christoffer, Svane Maria Saur, Veedfald Simon, Gade-Rasmussen Birthe, Hansen Torben, Madsbad Sten
机构信息
Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
出版信息
Eur J Case Rep Intern Med. 2021 Mar 31;8(3):002352. doi: 10.12890/2021_002352. eCollection 2021.
UNLABELLED
Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months' follow-up.
LEARNING POINTS
Genetic testing is important in patients with neonatal diabetes.Sulfonylurea is the standard treatment for patients with the most common mutation ().We present the novel use of a GLP-1 receptor agonist as effective add-on therapy in a patient with neonatal diabetes and insufficient effect of sulfonylurea monotherapy.
未标注
磺脲类单药治疗是最常见类型的永久性新生儿糖尿病患者的标准治疗方法，但并不总是足够有效。我们首次报告了1例成功使用胰高血糖素样肽-1（GLP-1）受体激动剂作为附加治疗的新生儿糖尿病患者，该患者接受磺脲类单药治疗效果不佳。在26个月的随访结束时，糖化血红蛋白（HbA1c）水平维持在48 mmol/mol（6.5%），血糖得到良好控制。
学习要点
基因检测对新生儿糖尿病患者很重要。磺脲类药物是最常见突变患者的标准治疗方法。我们展示了GLP-1受体激动剂作为附加治疗在1例新生儿糖尿病且磺脲类单药治疗效果不佳患者中的新用途。
Zotero 插件